Bristol-Myers Squibb Clinical Trial Pipeline — 306 Active Studies

Phase 1: 44, Phase 2: 70, Phase 3: 90, Other: 102

Bristol-Myers Squibb's clinical pipeline is defined by its foundational immuno-oncology franchise — Opdivo (nivolumab, PD-1) and Yervoy (ipilimumab, CTLA-4) — plus a growing cell therapy portfolio. The Opdivo + Yervoy combination remains one of the most broadly applied IO regimens in oncology, with ongoing trials across virtually every solid tumor type. In hematology, Breyanzi (lisocabtagene maraleucel) for large B-cell lymphoma and Abecma (idecabtagene vicleucel) for multiple myeloma represent BMS's CAR-T franchise, with active trials moving these therapies into earlier lines. Their cardiovascular drug mavacamten (Camzyos) and factor XIa inhibitor milvexian are advancing in a rejuvenated cardiovascular pipeline.

• Immuno-oncology (PD-1/CTLA-4)
• Cell therapy (CAR-T, lymphoma, myeloma)
• Hematology / combinations
• Cardiovascular (mavacamten, factor XIa)
• Fibrosis / inflammation

• Opdivo (nivolumab) — PD-1, pan-tumor IO
• Yervoy (ipilimumab) — CTLA-4, IO combination
• Breyanzi (lisocabtagene maraleucel) — CD19 CAR-T, B-cell lymphoma
• Abecma (idecabtagene vicleucel) — BCMA CAR-T, myeloma
• Reblozyl (luspatercept) — erythroid maturation, MDS/beta-thal
• Camzyos (mavacamten) — cardiac myosin, HCM

BMS's PD-1/CTLA-4 combination program generates dozens of new combination trials annually. For any company developing new IO agents or solid tumor therapies, tracking when BMS starts a new Opdivo+Yervoy+X trial in your indication is critical competitive intelligence.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Bristol-Myers Squibb's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Bristol-Myers Squibb may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.